Xinxin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xinxin Wang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bo Sun
Academy of Traditional Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou 450046, China
4 shared publications - Jinying Zhang
Academy of Traditional Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou 450046, China
4 shared publications - Mingsan Miao
Academy of Traditional Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou 450046, China
4 shared publications - Shuo Tian
Academy of Traditional Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou 450046, China
4 shared publications - Yuan Zuo
Academy of Traditional Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou 450046, China
4 shared publications - Ruiying Wang
Academy of Traditional Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou 450046, China
1 shared publication
Latest Publications
- Open Access
- 7 May 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 577
Engineered Plant-Derived Extracellular Vesicles: A Novel Strategy for Tumor-Targeted Therapy
Cancer remains a leading cause of premature death worldwide, posing a significant burden due to its high incidence and mortality. Radiotherapy and chemotherapy remain the most well-established and effective modalities in the current oncological therapeutic arsenal. However, their efficacy is often limited by toxicities owing to their non-selective targeting of rapidly dividing cells and consequent damage to healthy tissues. In recent years, advances in nanomedicine and biotechnology have drawn increasing attention to plant-derived extracellular vesicles (PDEVs) as an emerging, promising strategy for cancer therapy. As novel therapeutic vehicles, PDEVs offer key advantages, including high biocompatibility and low immunogenicity. However, their clinical translation has been significantly hampered by inherent limitations, including insufficient targeting specificity, low and uncontrollable drug-loading efficiency, and challenges in large-scale production and standardization. Current research is actively focused on overcoming these drawbacks through engineering strategies, for instance, surface modification with targeting peptides or antibodies to enhance targeting, alongside optimization of production and drug-loading processes. These developments underscore the potential of PDEVs as a promising platform for next-generation targeted cancer therapeutics. This review provides a comprehensive overview of PDEVs, covering their isolation, biogenesis, physicochemical properties, and anticancer applications. While summarizing these fundamental aspects, this review focuses on engineering strategies to enhance their active targeting capacity, offering theoretical insights to support their future role in cancer treatment.
- 7 May 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 577
Open AccessEngineered Plant-Derived Extracellular Vesicles: A Novel Strategy for Tumor-Targeted Therapy
Cancer remains a leading cause of premature death worldwide, posing a significant burden due to its high incidence and mortality. Radiotherapy and chemotherapy remain the most well-established and effective modalities in the current oncological therapeutic arsenal. However, their efficacy is often limited by toxicities owing to their non-selective targeting of rapidly dividing cells and consequent damage to healthy tissues. In recent years, advances in nanomedicine and biotechnology have drawn increasing attention to plant-derived extracellular vesicles (PDEVs) as an emerging, promising strategy for cancer therapy. As novel therapeutic vehicles, PDEVs offer key advantages, including high biocompatibility and low immunogenicity. However, their clinical translation has been significantly hampered by inherent limitations, including insufficient targeting specificity, low and uncontrollable drug-loading efficiency, and challenges in large-scale production and standardization. Current research is actively focused on overcoming these drawbacks through engineering strategies, for instance, surface modification with targeting peptides or antibodies to enhance targeting, alongside optimization of production and drug-loading processes. These developments underscore the potential of PDEVs as a promising platform for next-generation targeted cancer therapeutics. This review provides a comprehensive overview of PDEVs, covering their isolation, biogenesis, physicochemical properties, and anticancer applications. While summarizing these fundamental aspects, this review focuses on engineering strategies to enhance their active targeting capacity, offering theoretical insights to support their future role in cancer treatment.
- Open Access
- 28 February 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (3) , 311
Plant-Derived Vesicle-like Nanoparticles for Cancer Therapy: From Drug Delivery to Combined Immunotherapy
Plant-derived vesicle-like nanoparticles (PDVLNs) are a unique class of natural nanomaterials secreted by plant cells. Endowed with intrinsic biocompatibility, minimal immunogenicity, and a molecular cargo rich in lipids, proteins, nucleic acids, and unique metabolites, PDVLNs exhibit significant potential in cancer treatment. With the development of diverse engineering strategies and loading methods, PDVLNs have been well established as an ideal drug delivery platform for transporting a broad spectrum of anti-cancer agents, including nucleic acids, proteins, and conventional chemotherapeutics. Notably, accumulating evidence highlights PDVLNs as a novel nanoplatform for combined cancer immunotherapy. This review systematically summarizes the biogenesis, isolation methods, compositions, and anti-tumor activity and mechanisms of PDVLNs, emphasizing their synergistic applications with cancer immunotherapies. Finally, it also discusses the challenges related to production optimization, delivery efficiency, safety issues, and clinical translation facing current research. In the future, as mechanistic insights deepen and nanotechnology advances, PDVLNs are poised to become next-generation immunomodulatory nanoplatforms for enhanced cancer immunotherapy.
- 28 February 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (3) , 311
Open AccessPlant-Derived Vesicle-like Nanoparticles for Cancer Therapy: From Drug Delivery to Combined Immunotherapy
Plant-derived vesicle-like nanoparticles (PDVLNs) are a unique class of natural nanomaterials secreted by plant cells. Endowed with intrinsic biocompatibility, minimal immunogenicity, and a molecular cargo rich in lipids, proteins, nucleic acids, and unique metabolites, PDVLNs exhibit significant potential in cancer treatment. With the development of diverse engineering strategies and loading methods, PDVLNs have been well established as an ideal drug delivery platform for transporting a broad spectrum of anti-cancer agents, including nucleic acids, proteins, and conventional chemotherapeutics. Notably, accumulating evidence highlights PDVLNs as a novel nanoplatform for combined cancer immunotherapy. This review systematically summarizes the biogenesis, isolation methods, compositions, and anti-tumor activity and mechanisms of PDVLNs, emphasizing their synergistic applications with cancer immunotherapies. Finally, it also discusses the challenges related to production optimization, delivery efficiency, safety issues, and clinical translation facing current research. In the future, as mechanistic insights deepen and nanotechnology advances, PDVLNs are poised to become next-generation immunomodulatory nanoplatforms for enhanced cancer immunotherapy.
- Top Cited PapersOpen Access
- 10 January 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Plant-derived exosome-like nanovesicles: dual-function platforms for anticancer therapy and drug delivery
Plant-derived exosome-like nanovesicles (PDELNs) are nanoscale bilayered lipid vesicles secreted by plant cells that encapsulate a range of bioactive cargo
- 10 January 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Top Cited PapersOpen AccessPlant-derived exosome-like nanovesicles: dual-function platforms for anticancer therapy and drug delivery
Plant-derived exosome-like nanovesicles (PDELNs) are nanoscale bilayered lipid vesicles secreted by plant cells that encapsulate a range of bioactive cargo
- Open Access
- 28 July 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (8) , 1095
A New Perspective on Regenerative Medicine: Plant-Derived Extracellular Vesicles
Plant-derived extracellular vesicles (PDEVs) are nanoscale, phospholipid bilayer-enclosed vesicles secreted by living cells through cytokinesis under physiological and pathological conditions. Owing to their high biocompatibility and stability, PDEVs have attracted considerable interest in regenerative medicine applications. They can exhibit the capacity to enhance cellular proliferation, migration, and multi-lineage differentiation through immunomodulation, anti-inflammation effects, antioxidative protection, and tissue regeneration mechanisms. Given their abundant availability, favorable safety profile, and low immunogenicity risks, PDEVs have been successfully employed in therapeutic interventions for skeletal muscle disorders, cardiovascular diseases, neurodegenerative conditions, and tissue regeneration applications. This review mainly provides a comprehensive overview of PDEVs, systematically examining their biological properties, standardized isolation and characterization methodologies, preservation techniques, and current applications in regenerative medicine. Furthermore, we critically discuss future research directions and clinical translation potential, aiming to facilitate the advancement of PDEV-based therapeutic strategies.
- 28 July 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (8) , 1095
Open AccessA New Perspective on Regenerative Medicine: Plant-Derived Extracellular Vesicles
Plant-derived extracellular vesicles (PDEVs) are nanoscale, phospholipid bilayer-enclosed vesicles secreted by living cells through cytokinesis under physiological and pathological conditions. Owing to their high biocompatibility and stability, PDEVs have attracted considerable interest in regenerative medicine applications. They can exhibit the capacity to enhance cellular proliferation, migration, and multi-lineage differentiation through immunomodulation, anti-inflammation effects, antioxidative protection, and tissue regeneration mechanisms. Given their abundant availability, favorable safety profile, and low immunogenicity risks, PDEVs have been successfully employed in therapeutic interventions for skeletal muscle disorders, cardiovascular diseases, neurodegenerative conditions, and tissue regeneration applications. This review mainly provides a comprehensive overview of PDEVs, systematically examining their biological properties, standardized isolation and characterization methodologies, preservation techniques, and current applications in regenerative medicine. Furthermore, we critically discuss future research directions and clinical translation potential, aiming to facilitate the advancement of PDEV-based therapeutic strategies.